Leading Element Driving Change in the Inflammatory Bowel Disease Treatment Market in 2025: The Surge In Inflammatory Bowel Diseases Spurs Growth In Treatment Market Driver

Which drivers are expected to have the greatest impact on the over the inflammatory bowel disease treatment market's growth?
The increase in Crohn's disease and ulcerative colitis incidences is significantly contributing to the growth of the inflammatory bowel disease treatment market. Inflammatory bowel diseases like Crohn's disease and ulcerative colitis result in inflammation and ulcers (sores) within the digestive tracts. The escalating numbers of Crohn's disease and ulcerative colitis cases are anticipated to heighten the demand for treatments of inflammatory bowel disease, primarily due to their effectiveness in reducing bowel inflammation and minimizing and avoiding medical complications. For instance, research published in March 2022 in the United States National Library of Medicine, reveals that approximately 1.6 million Americans are currently living with inflammatory bowel disease (either Crohn's disease or ulcerative colitis). Additionally, roughly 70,000 new cases of IBD are reported annually in the USA. Therefore, the rising instances of Crohn's disease and ulcerative colitis are projected to accelerate the growth of the inflammatory bowel disease treatment market.

Get Your Inflammatory Bowel Disease Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

What is the future CAGR of the inflammatory bowel disease treatment market, and how will it impact industry expansion?
Recently, there has been a significant increase in the market size of the treatment for inflammatory bowel disease. In 2025, it is projected to reach $27.45 billion, up from $25.26 billion in 2024, at a compound annual growth rate (CAGR) of 8.6%. The growth experienced in the previous period can be linked to factors such as a rise in the prevalence of inflammatory bowel disease, heightened demand for biologics and immunomodulators, advancements made in treatment options, an aging demographic, and enhanced awareness about the disease.

The market for treating inflammatory bowel disease is anticipated to witness substantial expansion in the forthcoming years, rising to $40.27 billion by 2029 with a compound annual growth rate of 10.1%. The predicted growth trajectory for this period can be linked to factors such as heightened investment in research and development activities, escalating demand for biosimilars, an increased prevalence of inflammatory bowel disease in developing markets, surging demand for tailor-made medicine, and the inclusion of precision medicine in the treatment of IBD. Noteworthy advancements forecasted for this period encompass an augmentation in product launches and approvals, individualized dosage and treatment strategies in managing IBD, employing telemedicine for distance monitoring of IBD patients, delving into therapies based on microbiome for IBD, and welcoming value-based care approaches in IBD treatment.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What are the most significant trends transforming the inflammatory bowel disease treatment market today?
A significant emerging trend in the inflammatory bowel disease treatment market is the advancement of technology. Major players in this sector are prioritizing AI-based registries in order to stay competitive. An example of this is seen in May 2024, when Verantos, an organization based in California that specializes in real-world evidence (RWE), introduced the Inflammatory Bowel Disease Pragmatic Registry. This registry employs sophisticated artificial intelligence to produce high-quality real-world evidence (RWE) related to ulcerative colitis while also spanning Crohn's disease. The registry's goal is to expedite the creation of effective therapies by offering an exhaustive dataset encapsulating over 3 billion data points concerning patient care. This enables biopharma researchers to gain in-depth knowledge about the severity of diseases, efficacy of treatments, and clinical results, through the usage of both structured and unstructured electronic health record data.

Which key market segments comprise the inflammatory bowel disease treatment market and drive its revenue growth?
The inflammatory bowel disease treatment market covered in this report is segmented -

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn's Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6704

What regions are at the forefront of inflammatory bowel disease treatment market expansion?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the inflammatory bowel disease treatment market?
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Is Covered In The Inflammatory Bowel Disease Treatment Global Market Report?

•Market Size Forecast: Examine the inflammatory bowel disease treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the inflammatory bowel disease treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the inflammatory bowel disease treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the inflammatory bowel disease treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the inflammatory bowel disease treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the inflammatory bowel disease treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the inflammatory bowel disease treatment market.
•Competitive Landscape: Review strategic developments in the inflammatory bowel disease treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.